PKM and experimental autoimmune encephalomyelitis: It is reported that the PKM2 inhibitor suppresses glycolysis and Th17 differentiation by inhibiting PK activity, thereby alleviating disease activity in experimental autoimmune encephalomyelitis (Kono et al., 2019).